Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The More Life CompanyFRA:20MP Current Ratio is 1.71 as of Mar. 2026, which is 91% below its 10-year median of 18.39. The stock has 3 warning signs investors should review. Among 995 Drug Manufacturers companies, The More Life Company ranks worse than 57.99% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. The More Life Company's current ratio for the quarter that ended in Mar. 2026 was 1.71.
The More Life Company has a current ratio of 1.71. It generally indicates good short-term financial strength.
The historical rank and industry rank for The More Life Company's Current Ratio or its related term are showing as below:
FRA:20MP'
s Current Ratio Range Over the Past 10 Years
Min: 1.71 Med: 18.39 Max: 36.23
Current: 1.71
During the past 7 years, The More Life Company's highest Current Ratio was 36.23. The lowest was 1.71. And the median was 18.39.
FRA:20MP's Current Ratio is ranked worse than 57.99% of 995
companies
in the Drug Manufacturers industry
Industry Median: 1.96
vs FRA:20MP: 1.71
The More Life Company (FRA:20MP) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
The More Life Company Current Ratio Related Terms
The More Life Company Current Ratio Historical Data
* Premium members only.
The historical data trend for The More Life Company's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, The More Life Company's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
The More Life Company Current Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, The More Life Company's Current Ratio distribution charts can be found below:
* The bar in red indicates where The More Life Company's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The More Life Company (FRA:20MP) has a Current Ratio of 1.71 as of Mar. 2026. This is 91% below median its historical median of 18.39. Over the past decade, The More Life Company's Current Ratio has ranged from 1.71 to 36.23. According to the industry distribution chart, The More Life Company ranks #577 out of 995 companies in the Drug Manufacturers industry, placing it in the top 58%.
Is The More Life Company's Current Ratio too high?
The More Life Company's current Current Ratio of 1.71 is 91% below median its 10-year median of 18.39. Over the past 10 years, this metric has ranged from a low of 1.71 to a high of 36.23. The Drug Manufacturers industry median Current Ratio is 1.96. The More Life Company's value of 1.71 is 12.8% below this industry median. Based on the distribution chart, The More Life Company ranks #577 out of 995 companies in the Drug Manufacturers industry, which is below the industry midpoint.
How does The More Life Company's Current Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, The More Life Company ranks #577 out of 995 companies for Current Ratio. This places The More Life Company in the lower half of its industry. The industry median Current Ratio is 1.96. The More Life Company's value of 1.71 is 12.8% below this benchmark. Historically, The More Life Company's own Current Ratio has ranged from 1.71 to 36.23 over the past decade. While the company's 10-year median is 18.39 vs. the industry median of 1.96, The More Life Company has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Drug Manufacturers company?
The median Current Ratio among Drug Manufacturers companies is 1.96, based on 995 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. The More Life Company's current Current Ratio of 1.71 is 12.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Current Ratio is 1.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. The More Life Company's current Current Ratio is 1.71, which is 91% below median its own 10-year median of 18.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is The More Life Company stock overvalued right now?
The More Life Company (FRA:20MP) has a current Current Ratio of 1.71. The current Current Ratio is 1.71, which is 91% below median its 10-year median of 18.39 and 12.8% below the Drug Manufacturers industry median of 1.96. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For The More Life Company (FRA:20MP), the current Current Ratio is 1.71 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Mountain Valley MD Holdings Inc is a Canada-based company. The firm, along with its subsidiaries, is engaged in implementing its Quicksome oral delivery technologies across a variety of molecules in nutraceutical, vaccine, and pharmaceutical drug applications. The company actively invests in and collaborates on pioneering biotechnologies that have the potential to revolutionize the human health and wellness landscape, drive sustainable increases in plant yields and agricultural farming practices, and broadly support animal husbandry health. The Company is a biotech company focused on advancing solutions to optimize human, animal, and plant health.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:20MP has been successfully added to your 
